FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections
GAITHERSBURG, Md.–(BUSINESS WIRE[1])–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat multi-drug resistant bacterial infectious diseases, today announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients. “The FDA’s decision...